Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$48 Million) in this Round
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat
Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to
NEW EPIDAREX PORTFOLIO COMPANY WILL DEVELOP NOVEL CYCLIC ASPIRATION SYSTEM TO REMOVE BLOOD CLOTS FROM THE BRAIN Bethesda, MD, June 23, 2021 — Epidarex Capital,
EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that
Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies. Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a
Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal nocturnal
Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action
Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at
New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small
© Copyright Epidarex 2022. All rights reserved.